Celecoxib/tramadol sold under the brand name Seglentis, is a fixed-dose combination of the anti-inflammatory celecoxib and the opioid tramadol used for the management and treatment of pain.Developed by Spanish pharmaceutical company Esteve, it was approved for medical use in the United States in October 2021. References
External links
"Celecoxib". Drug Information Portal. U.S. National Library of Medicine. "Tramadol hydrochloride". Drug Information Portal. U.S. National Library of Medicine. Clinical trial number NCT03108482 for "Co-crystal E-58425 vs Tramadol and Celecoxib for Moderate to Severe Acute Pain After Bunionectomy. Phase III Clinical Trial." at ClinicalTrials.gov
These groups include: 

Those who have used topical corticosteroids over a prolonged period of time
Those who have used corticosteroids to cover a large surface area
Those with broken skin barrier or extensive abrasions
Those who have recently undergone stress (such as illness, trauma, surgery)
Children under the age of 12HPA axis suppression is preventable by supplementation with glucocorticosteroids. If HPA axis suppression occurs, it is often reversed shortly after discontinuation of treatment. Pharmacology
Mechanism of action
Pharmacokinetics
Absorption of topical corticosteroids depends on several factors such as the vehicle, or delivery system used by the drug, the integrity of the epidermal barrier, and whether or not an occlusive bandage is used in combination with the drug.The absorption of topical betamethasone dipropionate is theoretically minuscule; however, if absorbed it follows the same pharmacokinetic profile that is typical of systemic corticosteroids. It is metabolized primarily by the liver by hydrolysis to its metabolites B17P (primary) and betamethasone and the 6β-hydroxy derivatives of those metabolites, and it is excreted primarily by the kidneys. Chemistry
Betamethasone dipropionate is a white to almost white crystalline powder. Regulation
Betamethasone dipropionate was patented by Merck in 1987, as an augmented cream/lotion, Diprolene in the U.S., and Disprosone in Europe. These patents expired in 2003 and 2007 respectively leading to generic production of betamethasone dipropionate. During this time other topical corticosteroids such as triamcinolone acetonide and clobetasol propionate also became available as generic creams.